Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SPR | P35270 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016589 | 0.83 | ALDH1A1 (0.35) | ALDH1A1NPC1ACHEMAPTMEN1 | |
| SCHEMBL6628043 | 0.83 | ALDH1A1 (0.35) | ALDH1A1NPC1ACHEMAPTMEN1 | |
| SCHEMBL21138284 | 0.83 | ALDH1A1 (0.39) | ALDH1A1NPC1ACHEMAPTMEN1 | |
| SCHEMBL27351769 | 0.83 | ALDH1A1 (0.35) | ALDH1A1NPC1ACHEMAPTMEN1 | |
| SCHEMBL17643412 | 0.83 | ALDH1A1 (0.35) | ALDH1A1NPC1ACHEMAPTMEN1 | |
| SCHEMBL26053287 | 0.83 | ALDH1A1 (0.35) | ALDH1A1NPC1ACHEMAPTMEN1 | |
| SCHEMBL7244108 | 0.81 | — | — | |
| SCHEMBL21814192 | 0.81 | — | — | |
| SCHEMBL13861172 | 0.81 | — | — | |
| SCHEMBL23275047 | 0.81 | MAPT (0.33) | MAPTGAAHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102807523-A | Method for preparing (2R,4R)-4-methyl-2-pipecolic acid | SHANGHAI AOBO BIO PHARMACEUTICAL TECH CO LTD | 2012-12-05 | — | — | CN | claimed |
| CN-102807523-A | Method for preparing (2R,4R)-4-methyl-2-pipecolic acid | SHANGHAI AOBO BIO PHARMACEUTICAL TECH CO LTD | 2012-12-05 | — | — | CN | disclosed |
| US-7968719-B2 | Indazole derivatives as inhibitors of hormone sensitive lipase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20090215824-A1 | INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE SENSITIVE LIPASE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
| US-7528155-B2 | Indazole derivatives as inhibitors of hormone sensitive lipase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-05-05 | — | — | US | disclosed |
| US-20050197348-A1 | Indazole derivatives as inhibitors of hormone sensitive lipase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215824-A1 | INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE SENSITIVE LIPASE | LIPE, PNLIP, CEL | ALDH1A1 479/4885NPC1 924/4885ACHE 217/4885 |
| US-20050197348-A1 | Indazole derivatives as inhibitors of hormone sensitive lipase | LIPE, PNLIP, CEL | ALDH1A1 479/4885NPC1 924/4885ACHE 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.